Ex-Novartis John Tsai Takes The Reins At Cardiovascular-Focused Forcefield Therapeutics

Heart Attack Damage Prevented In Mouse Studies

 
• By Andrew McConaghie
  
John Tsai
Formerly CMO at Novartis, Tsai fielded numerous offers before deciding to take on the dual Syncona and Forcefield Therapeutics role.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip